Oral semaglutide was also more cost-effective than subcutaneous semaglutide for all one-way sensitivity analyses, except when the cost of subcutaneous semaglutide was less than $975, although oral semaglutide remained cost-effective (Supplementary Figure 2)
Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Retatrutide (LY3437943) adds a third target the glucagon receptor making it a triple agonist studied for broader metabolic effects
For some people who are no longer breastfeeding and have medical clearance, a GLP-1 may be appropriate later on, but there is no universal best option immediately after birth
Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study)
These findings align with previous reports indicating the maintenance of stem-cell-like cancer cells in established carcinoma cell lines [31]
Patients taking both Rybelsus and levothyroxine should be monitored for increased thyroid hormone exposure